11:46 AM EST - YM BioSciences Inc. : announced the approval of nimotuzumab for marketing in Mexico. Nimotuzumab is a humanized monoclonal antibody that targets the epidermal growth factor receptor, licensed to company's majority-owned subsidiary, CIMYM BioSciences Inc., by CIMAB S.A. The company noted that Mexican regulatory authorities have approved nimotuzumab for the treatment of squamous cell carcinoma of the head and neck, adult glioma and pediatric glioma. The approval was granted to Laboratorios PiSA in Guadalajara, Mexico and nimotuzumab will be commercialized under the name VECTH. YM BioSciences Inc.
shares T.YM are trading up $0.28 at $1.93.
